Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.

Leila-Sophie OttenBerber PietMichel M van den HeuvelCatia MarzoliniRobin M J M van GeelJudith L GulikersDavid M BurgerJenneke LeentjensRob Ter Heine

Published in: European respiratory review : an official journal of the European Respiratory Society (2022)

Combinations of SMIs and DOACs often result in relevant DDIs that can be prevented by adjusting the DOAC dosage, separation of administration or switching between anticoagulants.

Keyphrases

direct oral anticoagulants
small molecule
venous thromboembolism
atrial fibrillation
single cell
cell therapy
protein protein
epidermal growth factor receptor
liquid chromatography
clinical practice